Hepatocyte Nuclear Factor 3-alpha
"Hepatocyte Nuclear Factor 3-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A forkhead transcription factor that is an essential activator of GLUCAGON gene expression.
| Descriptor ID |
D051541
|
| MeSH Number(s) |
D12.776.260.262.750 D12.776.260.950.249.500 D12.776.660.352.750 D12.776.930.318.750 D12.776.930.977.249.500
|
| Concept/Terms |
Hepatocyte Nuclear Factor 3-alpha- Hepatocyte Nuclear Factor 3-alpha
- Hepatocyte Nuclear Factor 3 alpha
- HNF-3alpha Protein
- HNF 3alpha Protein
- Forkhead Box A1 Protein
- Hepatocyte Nuclear Factor 3alpha
- HNF-3A Transcription Factor
- HNF 3A Transcription Factor
- Transcription Factor, HNF-3A
- Hepatocyte-Enriched Transcription Factor HNF-3A
- Hepatocyte Enriched Transcription Factor HNF 3A
|
Below are MeSH descriptors whose meaning is more general than "Hepatocyte Nuclear Factor 3-alpha".
Below are MeSH descriptors whose meaning is more specific than "Hepatocyte Nuclear Factor 3-alpha".
This graph shows the total number of publications written about "Hepatocyte Nuclear Factor 3-alpha" by people in this website by year, and whether "Hepatocyte Nuclear Factor 3-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatocyte Nuclear Factor 3-alpha" by people in Profiles.
-
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers. J Natl Cancer Inst. 2025 Jan 01; 117(1):188-197.
-
Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer. Mol Oncol. 2023 10; 17(10):2126-2146.
-
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022 01 01; 163(1).
-
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022 01; 601(7893):434-439.
-
Systematic functional interrogation of human pseudogenes using CRISPRi. Genome Biol. 2021 Aug 23; 22(1):240.
-
Cell lineage tracing links ERa loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype. Proc Natl Acad Sci U S A. 2021 05 25; 118(21).
-
An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia. 2020 08; 22(8):294-310.
-
Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J Clin Invest. 2020 04 01; 130(4):1782-1792.
-
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10.
-
Bioinformatic analysis suggests that UGT2B15 activates the Hippo-YAP signaling pathway leading to the pathogenesis of gastric cancer. Oncol Rep. 2018 Oct; 40(4):1855-1862.